By: Dulan Lokuwithana, SA News Editor
- Napo EU, a subsidiary being established by Jaguar Health (JAGX -15.6%) in Italy has chosen the AIM Italy to list, it was revealed in a webcast organized by the company and a sponsor of the SPAC.
- The sponsor of the proposed Post Pandemic Recovery special purpose acquisition company said that a group of multinational institutional investors had already sought an interest of up to 70% of the proposed offering, adding that it is likely to accept funds for the listed SPAC from next week.
- Through Napo EU, the company is seeking to obtain conditional marketing authorization in Europe for crofelemer for the indication of prophylaxis and/or symptomatic relief of inflammatory diarrhea in the “long-hauler” COVID-19 recovery patient population.
- Jaguar Health announced in November that it was in preliminary discussions with Swiss Growth Forum, a sponsor of a European SPAC for a potential merger of a yet-to-be-established European subsidiary.